Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07216781 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans

A Phase 1 study of Healthy Adults, sponsored by Minicircle.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
2
Study locations

NCT07216781: Recruiting Phase 1 study of Healthy Adults, sponsored by Minicircle.

NCT07216781 is a Phase 1 study of Healthy Adults that is actively recruiting participants, run by Minicircle. The registered enrollment target is 24 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07216781, a Phase 1 study of Healthy Adults, is actively recruiting participants, sponsored by Minicircle.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.

Primary Outcome

Serum α-Klotho protein concentration will be quantified using a validated enzyme-linked immunosorbent assay (ELISA). Results will be reported as picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.

Conditions Studied

Interventions

  • GENETIC Injectable Plasmid Klotho Gene Therapy

Study Locations (2)

Texas

  • Apeiron Center - Austin

Bay Islands

  • GARM Clinic - Roatán

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-10-06
Est. Completion 2026-08
Phase Phase 1
Minicircle

2 total trials

What NCT07216781 shows while recruiting

NCT07216781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which Injectable Plasmid Klotho Gene Therapy is the first listed.

NCT07216781 reports a single indexed study location in Texas, Bay Islands.

Frequently Asked Questions

What is clinical trial NCT07216781 about?

NCT07216781 is a clinical study titled "Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans". The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.

What is the current status of trial NCT07216781?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-10-06. Estimated completion is 2026-08.

What conditions does trial NCT07216781 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT07216781?

The interventions under investigation include: Injectable Plasmid Klotho Gene Therapy (GENETIC).

Who is sponsoring clinical trial NCT07216781?

This trial is sponsored by Minicircle, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07216781 being conducted?

This trial has 2 study locations across Texas, Bay Islands. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07216781's enrollment target sits among peer trials

24 27th of 33 higher than 6 of 33 other Healthy Adults trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07216781, the US trial registry maintained by the National Library of Medicine. NCT07216781 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.